NCT02338037View on ClinicalTrials.gov

Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 19, 2015

Primary Completion Date

August 4, 2017

Study Completion Date

March 15, 2024

Conditions
Metastatic Malignant Neoplasm in the Adult BrainPrimary Brain Tumor
Interventions
PROCEDURE

Therapeutic Conventional Surgery

Undergo tumor resection

PROCEDURE

Biopsy

Undergo biopsy

DRUG

Eribulin Mesylate

Given IV

PROCEDURE

Microdialysis

Undergo intracerebral microdialysis

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Eisai Inc.

INDUSTRY

lead

City of Hope Medical Center

OTHER

NCT02338037 - Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors | Biotech Hunter | Biotech Hunter